and Circle Pharma have entered a new research partnership and licence agreement to develop a new precision cancer treatment. The partnership aims to create a first-in-class cyclin inhibitor, potentially offering new hope for patients with hard-to-treat cancers. The gold standard of business intelligence.
Uncontrolled cell growth is a hallmark of most tumours and a key factor in their development. Genetic alterations, such as mutations or amplifications in genes that regulate cell division, contribute to malignant growth in many solid tumours. Boehringer targets the proteins involved in this process as a promising strategy for developing new treatments.
Existing methods of targeting cyclin-dependent kinases, which are crucial for cell cycle progression, frequently face challenges such as low selectivity and toxicity. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Circle Pharma’s approach involves creating macrocycle therapies that directly inhibit cyclins, thereby regulating cell division more precisely to overcome the limitations of existing treatments.
The latest deal will strengthen the oncology pipeline of Boehringer, which include.
